3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Motor Activity
2
Lymphoma
2
Leukemia
2
Sarcopenia
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Obesity
1
Neoplasms, Plasma Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Hodgkin Disease
1
Interventions
Cyclophosphamide
193
fludarabine phosphate
123
Peripheral Blood Stem Cell Transplantation
107
Etoposide
106
Mycophenolic Acid
95
Filgrastim
92
Doxorubicin
85
Whole-Body Irradiation
84
Tacrolimus
81
Brentuximab Vedotin
80
Melphalan
78
Busulfan
75
Radiotherapy
74
fludarabine
68
Cyclosporine
67
Vinblastine
65
Rituximab
60
Dacarbazine
56
Granulocyte Colony-Stimulating Factor
53
Gemcitabine
52
Antilymphocyte Serum
51
Bleomycin
50
Nivolumab
47
Methotrexate
47
Vincristine
46
Prednisone
45
Cytarabine
44
pembrolizumab
36
Carmustine
36
Bendamustine Hydrochloride
32
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
Resistance Training
×
Lymphoid
×
Clear all
NCT05556239
2025-12-08
STAY-STRONG
Rigshospitalet, Denmark
Phase NA
Completed
42 enrolled